SCHEMBL8399454

SCHEMBL8399454

COCCOCOc1ccc(Cl)cc1Br

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 6/20 0.52
SMN1; SMN2 Q16637 8/20 0.50
ALDH1A1 P00352 6/20 0.50
GAA P10253 2/20 0.48
LMNA P02545 3/20 0.48
MAPT P10636 2/20 0.47
HTT P42858 2/20 0.47
HPGD P15428 1/20 0.47
MEN1 O00255 4/20 0.46
KMT2A Q03164 4/20 0.46
TDP1 Q9NUW8 2/20 0.46
NPC1 O15118 1/20 0.46
RAB9A P51151 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
CYP1A2 P05177 1/20 0.44
CYP2D6 P10635 1/20 0.44
CYP2C9 P11712 1/20 0.44
CYP2C19 P33261 1/20 0.44
S1PR4 O95977 1/20 0.43
HTR2C P28335 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30451378 0.89 SMN1; SMN2 (0.61) KDM4ESMN1; SMN2ALDH1A1GAALMNA
SCHEMBL24252913 0.89 SMN1; SMN2 (0.61) KDM4ESMN1; SMN2ALDH1A1GAALMNA
SCHEMBL25244529 0.89 SMN1; SMN2 (0.61) KDM4ESMN1; SMN2ALDH1A1GAALMNA
SCHEMBL15674609 0.88 KDM4E (0.43) KDM4ESMN1; SMN2ALDH1A1GAALMNA
SCHEMBL29684781 0.87 KDM4E (0.60) KDM4ESMN1; SMN2ALDH1A1GAALMNA
SCHEMBL1371009 0.85 KDM4E (0.51) KDM4ESMN1; SMN2ALDH1A1GAALMNA
SCHEMBL15674547 0.81 PKM (0.49) KDM4ESMN1; SMN2ALDH1A1LMNAMAPT
SCHEMBL14785415 0.80 KDM4E (0.42) KDM4EALDH1A1LMNAMAPTHTT
SCHEMBL3199685 0.80 GAA (0.55) KDM4ESMN1; SMN2ALDH1A1GAALMNA
SCHEMBL1303864 0.79 ALDH1A1 (0.40) KDM4ESMN1; SMN2ALDH1A1LMNAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2917181-B1 HETEROARYL DERIVATIVES AND USES THEREOF JACOBUS PHARMACEUTICAL COMPANY INC (US) 2019-09-25 EP disclosed
US-9409893-B2 Heteroaryl derivatives and uses thereof JACOBUS PHARMACEUTICAL COMPANY, INC. (US) 2016-08-09 US disclosed
EP-2917181-A1 HETEROARYL DERIVATIVES AND USES THEREOF Jacobus Pharmaceutical Company, Inc. (US) 2015-09-16 EP disclosed
WO-2014074775-A1 HETEROARYL DERIVATIVES AND USES THEREOF JACOBUS PHARMACEUTICAL COMPANY, INC. (US) 2014-05-15 WO disclosed
US-20140135320-A1 HETEROARYL DERIVATIVES AND USES THEREOF JACOBUS PHARMACEUTICAL COMPANY, INC. (US) 2014-05-15 US disclosed
US-5929107-A INHIBITORS OF ACYL-COA:CHOLESTEROL ACYLTRANSFERASE TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 1999-07-27 US disclosed
EP-0585913-B1 Condensed heterocyclic compounds, their production and use TAKEDA CHEMICAL INDUSTRIES LTD (JP) 1997-12-29 EP disclosed
US-5700810-A Condensed heterocyclic compounds, their production and use TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 1997-12-23 US disclosed
US-5492929-A ENZYME INHIBITORS, ANTICHOLESTEROL AGENTS TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 1996-02-20 US disclosed
US-5482967-A LOWERING CHOLESTEROL TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 1996-01-09 US disclosed
EP-0602598-A1 3-Phenylindolyl-, -benzofuranyl- and -benzothienyl- alkylcarboxanilides, their production and use Takeda Chemical Industries, Ltd. (JP) 1994-06-22 EP disclosed
EP-0585913-A2 Condensed heterocyclic compounds, their production and use TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 1994-03-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140135320-A1 HETEROARYL DERIVATIVES AND USES THEREOF ABCC1, CYP3A43, ABCB1 KDM4E 2224/4885SMN1; SMN2 4777/4885ALDH1A1 3317/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.